Loading...
Loading...
In a report published Friday, Jefferies & Company reiterated its Hold rating on Amedisys
AMED, but lowered its price target from $14.00 to $9.00.
Jefferies noted, “While we continue to believe that home nursing -- being the lowest-cost pre- and post-acute care option -- will have a key place in the continuum of care longer-term, AMED faces numerous near-term headwinds that will pressure its earnings outlook and the stock's valuation. Until these challenges dissipate, we recommend that investors stay on the sidelines.”
Amedisys closed on Thursday at $10.50.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in